rct
    2022
    High Quality

    Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28

    Unknown authors

    Published in JAMA Ophthalmol

    Key Findings

    At 10 years, lutein/zeaxanthin substitution for beta-carotene was associated with reduced progression to late AMD and lower lung cancer risk.

    Conclusions

    Confirms lutein/zeaxanthin as the preferred carotenoid in AMD formulas.

    Supplements Studied

    Zeaxanthin
    Compound

    Long-term follow-up favoured lutein/zeaxanthin over beta-carotene for AMD progression and safety.

    Lutein
    Compound

    Substituting lutein/zeaxanthin for beta-carotene reduced progression to late AMD over ten years.

    At 10 years, lutein/zeaxanthin substitution for beta-carotene was associated with reduced progression to late AMD and lower lung cancer risk.

    Related Health Concerns

    Vision Changes
    Cancer
    Macular Degeneration

    Study Details

    Year:2022
    Quality Score:8/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.